Showing results (1651-1660 of 1,858) with videos related to

Sort By:
Pageof 186
Plos One|August 1, 2012
High prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany: a prospective screening analysis of 28,809 patientsJohannes Vermehren, Beate Schlosser, Diana Domke, et al.
European Journal of Emergency Medicine : Official Journal of the European Society for Emergency Medicine|April 25, 2022
Prospective validation of a transcriptomic severity classifier among patients with suspected acute infection and sepsis in the emergency departmentNoa Galtung, Eva Diehl-Wiesenecker, Dana Lehmann, et al.
Cancers|July 7, 2019
In Vivo Detection of Circulating Tumor Cells in High-Risk Non-Metastatic Prostate Cancer Patients Undergoing RadiotherapyShukun Chen, Gerlinde Tauber, Tanja Langsenlehner, et al.
Plos One|January 10, 2013
Molecular imaging of microglial activation in amyotrophic lateral sclerosisPhilippe Corcia, Clovis Tauber, Johnnie Vercoullie, et al.
The Journal of Clinical Endocrinology and Metabolism|January 4, 2013
Growth hormone therapy for children and adolescents with Prader-Willi syndrome is associated with improved body composition and metabolic status in adulthoodMuriel Coupaye, Françoise Lorenzini, Célia Lloret-Linares, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 29, 2012
Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short statureAudrey De Rocca Serra-Nédélec, Thomas Edouard, Karine Tréguer, et al.
International Immunopharmacology|June 5, 2023
Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseasesXavier Boumaza, Margaux Lafaurie, Emmanuel Treiner, et al.
European Journal of Endocrinology|December 22, 1999
GH deficiency in adults: an epidemiological approachG Sassolas, F B Chazot, P Jaquet, et al.
Lancet (London, England)|March 19, 2023
Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trialRoland Tschismarov, Pierre Van Damme, Clara Germain, et al.
Vaccine|June 30, 2009
Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis CHeiner Wedemeyer, Elisabeth Schuller, Verena Schlaphoff, et al.
Pageof 186